<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02250612</url>
  </required_header>
  <id_info>
    <org_study_id>SYL040012_IV</org_study_id>
    <secondary_id>2013-002947-27</secondary_id>
    <nct_id>NCT02250612</nct_id>
  </id_info>
  <brief_title>SYL040012, Treatment for Open Angle Glaucoma</brief_title>
  <acronym>SYLTAG</acronym>
  <official_title>A Phase II, Observer Masked, Active Controlled Study of SYL040012 for the Treatment of Elevated Intraocular Pressure in Patients With Open-angle Glaucoma or Ocular Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sylentis, S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sylentis, S.A.</source>
  <brief_summary>
    <textblock>
      The purpose of this double-masked, randomized, controlled study is to assess the safety and
      ocular hypotensive efficacy of four different doses of SYL040012 (bamosiran) eye drops
      compared to Timolol maleate 0.5% after 28 treatment days in patients with elevated
      intraocular pressure.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in the mean diurnal IOP within each treatment arm</measure>
    <time_frame>Day 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the mean diurnal IOP within each treatment arm</measure>
    <time_frame>Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean diurnal IOP change of the different doses of SYL040012 eye drops versus Timolol maleate 0.5%</measure>
    <time_frame>Day 14 and Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the Glaucoma Quality of Life questionnaire (GQL-15) scores within each treatment arm</measure>
    <time_frame>Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in vital signs and laboratory parameters as measurements of systemic tolerability</measure>
    <time_frame>Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Adverse Events Appearance</measure>
    <time_frame>During site visits (Screening, baseline, Day 7, Day 14, Day 21, Day 28 and Day 29) each subject will be asked about development of any AEs</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">184</enrollment>
  <condition>Open Angle Glaucoma</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>SYL040012 (bamosiran) eye drops Dose A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 drop in each eye once daily for 28 consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SYL040012 (bamosiran) eye drops Dose B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 drop in each eye once daily for 28 consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SYL040012 (bamosiran) eye drops Dose C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 drop in each eye once daily for 28 consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SYL040012 (bamosiran) eye drops Dose D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 drop in each eye once daily for 28 consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Timolol maleate 0.5% ophthalmic solution</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 drop in each eye twice daily for 28 consecutive days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1 drop of SYL040012 (bamosiran) Dose A</intervention_name>
    <arm_group_label>SYL040012 (bamosiran) eye drops Dose A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1 drop of SYL040012 (bamosiran) Dose B</intervention_name>
    <arm_group_label>SYL040012 (bamosiran) eye drops Dose B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1 drop of SYL040012 (bamosiran) Dose C</intervention_name>
    <arm_group_label>SYL040012 (bamosiran) eye drops Dose C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1 drop of SYL040012 (bamosiran) Dose D</intervention_name>
    <arm_group_label>SYL040012 (bamosiran) eye drops Dose D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1 drop of timolol maleate</intervention_name>
    <description>0.5 %</description>
    <arm_group_label>Timolol maleate 0.5% ophthalmic solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients older than 18 years of either sex

          -  Good or fair general health as assessed by the investigator.

          -  Signed informed consent prior to any clinical trial-related procedures

          -  Diagnosis of open angle glaucoma (OAG) or ocular hypertension (OHT)

          -  Post-washout mean IOP above target range

          -  BCVA 1.0 logMAR or better by ETDRS in each eye (equivalent to 20/200)

          -  Stable visual field

          -  Central corneal thickness 480-620 μm

          -  Shaffer gonioscopic grade of ≥ 3 (in at least 3 quadrants) in both eyes

        Exclusion Criteria:

          -  Pregnant or breastfeeding females

          -  Females of childbearing potential not willing to use a medically acceptable
             contraceptive method

          -  Clinically significant systemic disease

          -  Changes of systemic medication that could have a substantial effect on IOP

          -  Known hypersensitivity to any component of the formulations

          -  Unable to comply with the clinical trial requirements

          -  Clinically significant abnormalities in laboratory tests

          -  Severe visual field defect

          -  Any secondary glaucoma

          -  Pseudoexfoliation or pigment dispersion component, history of angle closure or narrow
             angles.

          -  IOP ≥ 35 mm Hg in any eye

          -  Previous non-laser glaucoma surgery or glaucoma laser procedures (e.g., laser
             trabeculoplasty) and refractive surgery

          -  Any ocular surgery or laser treatment, cataract extraction or ocular trauma within 6
             months prior to Baseline

          -  Evidence of ocular infection, inflammation, clinically significant blepharitis or
             conjunctivitis at baseline (Visit 0), or a history of herpes simplex keratitis

          -  Clinically significant ocular disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Sall Research Medical Center</name>
      <address>
        <city>Artesia</city>
        <state>California</state>
        <zip>90701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Bay Eye Associates</name>
      <address>
        <city>Petaluma</city>
        <state>California</state>
        <zip>94954</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eye Care Centers Management, Inc (Clayton Eye Center)</name>
      <address>
        <city>Morrow</city>
        <state>Georgia</state>
        <zip>30260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taustin Eye Center</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Tallin Central Hospital</name>
      <address>
        <city>Tallin</city>
        <zip>10138</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eye Clinic Dr. Krista Turman</name>
      <address>
        <city>Tallin</city>
        <zip>13419</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tartu University Hospital</name>
      <address>
        <city>Tartu</city>
        <zip>50406</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinic Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <zip>39106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität München</name>
      <address>
        <city>München</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster</name>
      <address>
        <city>Münster</city>
        <zip>D-48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Torrevieja</name>
      <address>
        <city>Torrevieja</city>
        <state>Alicante</state>
        <zip>03186</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Jerez</name>
      <address>
        <city>Jerez de la Frontera</city>
        <state>Cádiz</state>
        <zip>11407</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Universidad Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Pontevedra</name>
      <address>
        <city>Pontevedra</city>
        <zip>36001</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Oftalmobiología Aplicada</name>
      <address>
        <city>Valladolid</city>
        <zip>47011</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Estonia</country>
    <country>Germany</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 5, 2014</study_first_submitted>
  <study_first_submitted_qc>September 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2014</study_first_posted>
  <last_update_submitted>January 27, 2016</last_update_submitted>
  <last_update_submitted_qc>January 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SYL040012</keyword>
  <keyword>bamosiran</keyword>
  <keyword>siRNA</keyword>
  <keyword>RNAi</keyword>
  <keyword>Glaucoma</keyword>
  <keyword>Ocular hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Timolol</mesh_term>
    <mesh_term>Maleic acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

